Cas:190965-43-6 2-Bromo-5-propoxybenzoic acid manufacturer & supplier

Chemical Name:2-Bromo-5-propoxybenzoic acid

CAS.NO:190965-43-6

Synonyms:2-bromo-5-n-propyloxybenzoic acid

Molecular Formula:C₁₀H₁₁BrO₃

Molecular Weight:259.09700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.53000

Exact Mass:257.98900

LogP:2.93610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-bromo-5-n-propyloxybenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-5-n-propyloxybenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-bromo-5-n-propyloxybenzoic acid Use and application,2-bromo-5-n-propyloxybenzoic acid technical grade,usp/ep/jp grade.

Related News: Health officials said it remained unclear where he had developed the disease. 2-Bromo-5-propoxybenzoic acid manufacturer The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. 2-Bromo-5-propoxybenzoic acid supplier The fine chemical industry includes fine chemicals and special chemicals. Fine chemical products have the characteristics of a small amount of production, relatively specific application fields, and long and complex industrial chains. They are mainly used in medicine, pesticides, dyes, liquid crystals and other fields. 2-Bromo-5-propoxybenzoic acid vendor Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. 2-Bromo-5-propoxybenzoic acid factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.